The Trials Enabling Program (TEP)
In an Australian first, we’ve established the Trials Enabling Program (TEP) that will help people with blood cancer access promising new drugs through international clinical trials.
In 2015, the Leukaemia Foundation set out to address the lack of international clinical trial presence in Australia. We partnered with the nation’s leading blood cancer clinical trial group – the Australasian Leukaemia & Lymphoma Group (ALLG) – to establish TEP.
TEP is a mechanism that improves access of patients in Australia to the latest ground-breaking research and new therapies by bringing international clinical trials to Australia. TEP will deliver new therapeutic drugs to patients years ahead of the expected availability on the Australian market.
This innovative program is the first time an Australian charity has established a grant partnership to help patients access international blood cancer trials.